A Novel Trial of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO).

Cureus · 2022 · PMC9682970 · PMID 36425049

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

The study did not achieve significance in its primary endpoint, change in the average overactive bladder-symptom composite score, between baseline (Visit 2) and Visit 4.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.